Chapter 12 : Coagulation and Innate Immunity

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Coagulation and Innate Immunity, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817671/9781555812911_Chap12-1.gif /docserver/preview/fulltext/10.1128/9781555817671/9781555812911_Chap12-2.gif


This chapter summarizes the current information on the linkage between the regulation of the coagulation and inflammatory responses to infection. Inflammation can affect coagulation status in less overt fashions. Inflammatory mediators such as interleukin-6 (IL-6) can not only increase platelet production, but the platelets that are generated are more thrombogenic, demonstrating an increased sensitivity to platelet agonists like thrombin. Among the major anticoagulant mechanisms, the protein C anticoagulant pathway is the most complex and appears to be the most impacted by acute inflammatory responses. Both antithrombin and protein C inhibitor play major roles in inactivating thrombomodulin (TM)-bound thrombin, resulting in a half-life for the bound thrombin of about 1 to 2 s. The difference in efficacy in modulating the host response to bacterial and endotoxin infusion between artificial anticoagulants and the natural anticoagulants suggests that the anti-inflammatory activities of the natural anticoagulants may be very important aspects of their physiological functions. The role of cleavage of the protease-activated receptors in activated protein C (APC) function remains to be fully elucidated. Most of the downstream events following activation of these receptors enhance inflammation. TM accelerates thrombin activation of a plasma procarboxypeptidase B, often named thrombin-activatable fibrinolysis inhibitor (TAFI). It is now recognized that even the statins thought originally to function by lowering cholesterol have important anti-inflammatory effects as well. Further identification of the links between inflammation and thrombosis should provide novel approaches to new diagnostics and therapeutics.

Citation: Esmon C. 2004. Coagulation and Innate Immunity, p 241-253. In Kaufmann S, Medzhitov R, Gordon S (ed), The Innate Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555817671.ch12
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

A simplified view of the regulation of blood coagulation by the protein C pathway. Factor VIIa binds to tissue factor (TF) to activate factor X, generating factor Xa. Factor Xa then binds to factor Va. The complex of factors Xa and V converts prothrombin (Pro) to thrombin (T).Thrombin can then either bind to TM or carry out procoagulant reactions like fibrin formation or platelet activation. When bound to TM, thrombin can activate protein C (PC) to APC. This process is enhanced when protein C is bound to EPCR. APC bound to EPCR cleaves substrates other than factor Va. APC dissociates from EPCR and can then interact with protein S to inactivate factor Va. The middle row shows inactivation of the factor IXa (IXa)-factor VIIIa complex by APC. In this case, factor V participates with APC and protein S in the inactivation of factor VIIIa. In the bottom row, the plasma proteinase inhibitors that regulate the protein C activation complex and the anticoagulant complex of APC and protein S are illustrated. α-AT, α-antitrypsin; α-Mac, α-macroglobulin; PCI, protein C inhibitor; and AT, antithrombin. TAFI is activated (TAFIa) by the thrombin-TM complex. TAFIa then inactivates C5a. For simplicity, the activation of factors VII,V, and VIII is not shown. Figure modified with permission from Esmon, 1999, copyright F. K. Schattauer.

Citation: Esmon C. 2004. Coagulation and Innate Immunity, p 241-253. In Kaufmann S, Medzhitov R, Gordon S (ed), The Innate Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555817671.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

Thrombin is a multifunctional enzyme and generates the procoagulant, anticoagulant, inflammatory, and mitogenic responses. These responses serve to shift the hemostatic balance. EC, endothelial cell; PMNs, polymorphonucleocytes; PAF, platelet-activating factor; PDGF, platelet-derived growth factor; TGF-β, transforming growth factor β; CD40L, CD40 ligand; MCP-1, macrophage chemotactic protein-1. (From Esmon, 1993, with permission from the vol. 9, copyright by Annual Reviews.)

Citation: Esmon C. 2004. Coagulation and Innate Immunity, p 241-253. In Kaufmann S, Medzhitov R, Gordon S (ed), The Innate Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555817671.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3

Impact of inflammation on coagulation.

Citation: Esmon C. 2004. Coagulation and Innate Immunity, p 241-253. In Kaufmann S, Medzhitov R, Gordon S (ed), The Innate Immune Response to Infection. ASM Press, Washington, DC. doi: 10.1128/9781555817671.ch12
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Alberio, L.,, O. Safa,, K. J. Clemetson,, C. T. Esmon,, and G. L. Dale. 2000. Surface expression and functional characterization of α-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 95: 1694 1702.
2. André, P.,, K. S. Srinivasa Prasad,, C.V. Denis,, M. He,, J. M. Papalia,, R. O. Hynes,, D. R. Phillips,, and D. D. Wagner. 2002. CD40L stabilizes arterial thrombi by a β 3 integrin-dependent mechanism. Nat. Med. 8: 247 252.
3. Bajzar, L.,, J. Morser,, and M. Nesheim. 1996. TAFI, or Plasma Procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 271: 16603 16608.
4. Bar-Shavit, R.,, A. J. Kahn,, K. G. Mann,, and G. D. Wilner. 1986. Identification of a thrombin sequence with growth factor activity on macrophages. Proc. Natl. Acad. Sci. USA 83: 976 980.
5. Bernard, G. R.,, J. L. Vincent,, P. F. Laterre,, S. P. LaRosa,, J. F. Dhainaut,, A. Lopez-Rodriguez,, J. S. Steingrub,, G. E. Garber,, J. D. Helterbrand,, E.W. Ely,, C. J. Fisher, Jr., and the Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344: 699 709.
6. Bevers, E. M.,, P. Comfurius,, and R. F. A. Zwaal. 1991. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev. 5: 146 154.
7. Broze, G. J., Jr.,, T. J. Girard,, and W. F. Novotny. 1990. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 29: 7539 7546.
8. Burstein, S. A. 1997. Cytokines, platelet production and hemostasis. Platelets 8: 93 104.
9. Campbell, W.,, N. Okada,, and H. Okada. 2001. Carboxypeptidase R is an inactivator of complementderived inflammatory peptides and an inhibitor of fibrinolysis. Immunol. Rev. 180: 162 167.
10. Campbell, W. D.,, E. Lazoura,, N. Okada,, and H. Okada. 2002. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol. Immunol. 46: 131 134.
11. Conway, E. M.,, and R. D. Rosenberg. 1988. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol. Cell. Biol. 8: 5588 5592.
12. Conway, E. M.,, M. Van de Wouwer,, S. Pollefeyt,, K. Jurk,, H. Van Aken,, A. De Vriese,, J. I. Weitz,, H. Weiler,, P.W. Hellings,, P. Schaeffer,, J.M. Herbert,, D. Collen,, and G. Theilmeier. 2002. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor κB and mitogen-activated protein kinase pathways. J. Exp. Med. 196: 565 577.
13. Coughlin, S. R. 1994. Thrombin receptor function and cardiovascular disease. Trends Cardiovasc. Med. 4: 77 83.
14. Coughlin, S. R. 2000. Thrombin signalling and protease- activated receptors. Nature 407: 258 264.
15. Dahlbäck, B. 1991. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb. Haemost. 66: 49 61.
16. Dickneite, G. 1998. Antithrombin III in animal models of sepsis and organ failure. Sem. Thromb. Hemost. 24: 61 69.
17. Drake, T. A.,, J. H. Morrissey,, and T. S. Edgington. 1989. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am. J. Pathol. 134: 1087 1097.
18. Dreyfus, M.,, J. F. Magny,, F. Bridey,, H. P. Schwarz,, C. Planché,, M. Dehan,, and G. Tchernia. 1991. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N. Engl. J. Med. 325: 1565 1568.
19. Edgington, T. S.,, N. Mackman,, K. Brand,, and W. Ruf. 1991. The structural biology of expression and function of tissue factor. Thromb. Haemost. 66: 67 79.
20. Enkhbaatar, P.,, K. Okajima,, K. Murakami,, M. Uchiba,, H. Okabe,, K. Okabe,, and Y. Yamaguchi. 2000. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am. J. Respir. Crit. Care Med. 162: 1752 1759.
21. Esmon, C.T. 1993. Cell mediated events that control blood coagulation and vascular injury. Annu. Rev. Cell Biol. 9: 1 26.
22. Esmon, C.T. 2000. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 95: 1113 1116.
23. Esmon, C.T., 2001. Protein C, protein S, and thrombomodulin, p. 335 353. In R. W. Colman,, J. Hirsh,, V. J. Marder,, A. W. Clowes,, and J. N. George (ed.), Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott Williams & Wilkins, Philadelphia, Pa..
24. Esmon, C. T. 2002. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J. Exp. Med. 196: 561 564.
25. Esmon, C.T.,, J. Xu,, J. M. Gu,, D. Qu,, Z. Laszik,, G. Ferrell,, D. J. Stearns-Kurosawa,, S. Kurosawa,, F. B. Taylor, Jr.,, and N. L. Esmon. 1999. Endothelial protein C receptor. Thromb. Haemost. 82: 251 258.
26. Faust, S. N.,, M. Levin,, O. B. Harrison,, R. D. Goldin,, M. S. Lockhart,, S. Kondaveeti,, Z. Laszik,, C.T. Esmon,, and R. S. Heyderman. 2001. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med. 345: 408 416.
27. Fukudome, K.,, and C. T. Esmon. 1994. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J. Biol. Chem. 269: 26486 26491.
28. Giles, A. R.,, K. G. Mann,, and M. E. Nesheim. 1988. A combination of factor Xa and phosphatidylcholine- phosphatidylserine vesicles bypasses factor VIII in vivo. Br. J. Haematol. 69: 491 497.
29. Glaser, C. B.,, J. Morser,, J. H. Clarke,, E. Blasko,, K. McLean,, I. Kuhn,, R.-J. Chang,, J.-H. Lin,, L. Vilander,, W. H. Andrews,, and D. R. Light. 1992. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J. Clin. Invest. 90: 2565 2573.
30. Grey, S.,, H. Hau,, H. H. Salem,, and W. W. Hancock. 1993. Selective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-gamma, or PMA: modulation of effects on CD11b and CD14 but not CD25 or CD54 induction. Transplant. Proc. 25: 2913 2914.
31. Gruber, A.,, and J. H. Griffin. 1992. Direct detection of activated protein C in blood from human subjects. Blood 79: 2340 2348.
32. Gu, J.-M.,, J.T. B. Crawley,, G. Ferrell,, F. Zhang,, W. Li,, N. L. Esmon,, and C. T. Esmon. 2002. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J. Biol. Chem. 277: 43335 43343.
33. Han, X.,, R. Fiehler,, and G. J. Broze, Jr. 2000. Characterization of the protein Z-dependent protease inhibitor. Blood 96: 3049 3055.
34. Hancock, W.W.,, S.T. Grey,, L. Hau,, A. Akalin,, C. Orthner,, M. H. Sayegh,, and H. H. Salem. 1995. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 60: 1525 1532.
35. Heeb, M. J.,, A. Gruber,, and J. H. Griffin. 1991. Identification of divalent metal ion-dependent inhibition of activated protein C by alpha2-macroglobulin and alpha2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J. Biol. Chem. 266: 17606 17612.
36. Henn, V.,, J. R. Slupsky,, M. Gräfe,, I. Anagnostopoulos,, R. Förster,, G. Müller- Berghaus,, and R. A. Kroczek. 1998. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591 594.
37. Hong, S.,, D. C. Scherer,, N. Singh,, S. K. Mendiratta,, I. Serizawa,, Y. Koezuka,, and L. Van Kaer. 1999. Lipid antigen presentation in the immune system learned from CD1d knockout mice. Immunol. Rev. 169: 31 44.
38. Huang, Z.-F.,, D. Higuchi,, N. Lasky,, and G. J. Broze, Jr. 1997. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90: 944 951.
39. Jackman, R.W.,, D. L. Beeler,, L. Fritze,, G. Soff,, and R. D. Rosenberg. 1987. Human thrombomodulin gene is intron depleted: nucleic acid sequences of the cDNA and gene predict protein structure and suggest sites of regulatory control. Proc. Natl. Acad. Sci. USA 84: 6425 6429.
40. Joyce, D. E.,, L. Gelbert,, A. Ciaccia,, B. DeHoff,, and B.W. Grinnell. 2001. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276: 11199 11203.
41. Klein, N. J.,, C. A. Ison,, M. Peakman,, M. Levin,, S. Hammerschmidt,, M. Frosch,, and R. S. Heyderman. 1996. The influence of capsulation and lipooligosaccharide structure on neutrophil adhesion molecule expression and endothelial injury by Neisseria meningitidis. J. Infect. Dis. 173: 172 179.
42. Kurosawa, S.,, C. T. Esmon,, and D. J. Stearns- Kurosawa. 2000. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CDIIb/CDI8. J. Immunol. 165: 4697 4703.
43. Laszik, Z.,, A. Mitro,, F. B. Taylor, Jr.,, G. Ferrell,, and C.T. Esmon. 1997. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 96: 3633 3640.
44. Levi, M.,, and H. ten Cate. 1999. Disseminated intravascular coagulation. N. Engl. J. Med. 341: 586 592.
45. Liaw, P. C. Y.,, P. F. Neuenschwander,, M. D. Smirnov,, and C. T. Esmon. 2000. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J. Biol. Chem. 275: 5447 5452.
46. Liaw, P. C. Y.,, G. L. Ferrell,, and C. T. Esmon. 2002. A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J. Thromb. Haemost. 1: 662 670.
47. Lorant, D. E.,, K. D. Patel,, T. M. McIntyre,, R. P. McEver,, S. M. Prescott,, and G. A. Zimmerman. 1991. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J. Cell Biol. 115: 223 234.
48. Lupu, C.,, F. Lupu,, U. Dennehy,, V.V. Kakkar,, and M. F. Scully. 1995. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler. Thromb. Vasc. Biol. 15: 2055 2062.
49. Miller, D. L.,, R. Yaron,, and M. J. Yellin. 1998. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J. Leukoc. Biol. 63: 373 379.
50. Moody, D. B.,, T. Ulrichs,, W. Mühlecker,, D. C. Young,, S. S. Gurcha,, E. Grant,, J.-P. Rosat,, M. B. Brenner,, C. E. Costello,, G. S. Besra,, and S. A. Porcelli. 2000. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 404: 884 888.
51. Morrissey, J. H.,, H. Fakhrai,, and T. S. Edgington. 1987. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 50: 129 135.
52. Nesheim, M. E.,, W. M. Canfield,, W. Kisiel,, and K. G. Mann. 1982. Studies on the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J. Biol. Chem. 257: 1443 1447.
53. Oelschläger, C.,, J. Römisch,, A. Staubitz,, H. Stauss,, B. Leithäuser,, H. Tillmanns,, and H. Hölschermann. 2002. Antithrombin III inhibits nuclear factor κB activation in human monocytes and vascular endothelial cells. Blood 99: 4015 4020.
54. Oganesyan, V.,, N. Oganesyan,, S. Terzyan,, D. Qu,, Z. Dauter,, N. L. Esmon,, and C.T. Esmon. 2002. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J. Biol. Chem. 277: 24851 24854.
55. Opal, S. M.,, and C. T. Esmon. 2002. Benchto- bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit. Care 7: 23 38.
56. Palabrica, T.,, R. Lobb,, B. C. Furie,, M. Aronovitz,, C. Benjamin,, Y. M. Hsu,, S.A. Sajer,, and B. Furie. 1992. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359: 848 851.
57. Pendurthi, U. R.,, D. Alok,, and L.V. M. Rao. 1997. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: upregulation of poly(A) polymerase. Proc. Natl. Acad. Sci. USA 94: 12598 12603.
58. Raczkowski, C. A.,, M. Reichlin,, C. T. Esmon,, and P. C. Comp. 1987. Protein Z is a negatively responding acute phase protein. Blood 70: 393a. ( Abstract 1427.)
59. Regan, L. M.,, B. J. Lamphear,, C. F. Huggins,, F. J. Walker,, and P. J. Fay. 1994. Factor IXa protects factor VIIIa from activated protein C. J. Biol. Chem. 269: 9445 9452.
60. Rezaie, A. R. 2001. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J. Biol. Chem. 276: 15567 15570.
61. Rezaie, A. R.,, S. T. Cooper,, F. C. Church,, and C. T. Esmon. 1995. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J. Biol. Chem. 270: 25336 25339.
62. Riewald, M.,, R. J. Petrovan,, A. Donner,, B. M. Mueller,, and W. Ruf. 2002. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296: 1880 1882.
63. Sadler, J. E. 1997. Thrombomodulin structure and function. Thromb. Haemost. 78: 392 395.
64. Shu, F.,, H. Kobayashi,, K. Fukudome,, N. Tsuneyoshi,, M. Kimoto,, and T. Terao. 2000. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptordependent manner. FEBS Lett. 477: 208 212.
65. Simmonds, R. E.,, and D.A. Lane. 1999. Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: comparison with the structure of CD1/major histocompatibility complex α 1 and α 2 domains. Blood 94: 632 641.
66. Sims, P. J.,, F. M. Faioni,, T. Wiedmer,, and S. J. Shattil. 1988. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J. Biol. Chem. 263: 18205 18212.
67. Souter, P. J.,, S. Thomas,, A. R. Hubbard,, S. Poole,, J. Romisch,, and E. Gray. 2001. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit. Care Med. 29: 134 139.
68. Stearns-Kurosawa, D. J.,, S. Kurosawa,, J. S. Mollica,, G. L. Ferrell,, and C.T. Esmon. 1996. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. USA 93: 10212 10216.
69. Takano, S.,, S. Kimura,, S. Ohdama,, and N. Aoki. 1990. Plasma thrombomodulin in health and diseases. Blood 76: 2024 2029.
70. Taoka, Y.,, K. Okajima,, M. Uchiba,, K. Murakami,, N. Harada,, M. Johno,, and M. Naruo. 1998. Activated protein C reduces the severity of compression- induced spinal cord injury in rats by inhibiting activation of leukocytes. J. Neurosci. 18: 1393 1398.
71. Taylor, F. B., Jr.,, A. Chang,, C. T. Esmon,, A. D'Angelo,, S. Vigano-D'Angelo,, and K. E. Blick. 1987. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J. Clin. Invest. 79: 918 925.
72. Taylor, F. B., Jr.,, A. C. K. Chang,, G. T. Peer,, T. Mather,, K. Blick,, R. Catlett,, M. S. Lockhart,, and C. T. Esmon. 1991. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 78: 364 368.
73. Taylor, F. B., Jr.,, S. E. He,, A. C. K. Chang,, J. Box,, G. Ferrell,, D. Lee,, M. Lockhart,, G. Peer,, and C. T. Esmon. 1996. Infusion of phospholipid vesicles amplifies the local thrombotic response to TNF and anti-protein C into a consumptive response. Thromb. Haemost. 75: 578 584.
74. Taylor, F. B., Jr.,, D. J. Stearns-Kurosawa,, S. Kurosawa,, G. Ferrell,, A. C. K. Chang,, Z. Laszik,, S. Kosanke,, G. Peer,, and C. T. Esmon. 2000. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95: 1680 1686.
75. Uchiba, M.,, and K. Okajima. 1997. Antithrombin III (AT III) prevents LPS-induced vascular injury: novel biological activity of AT III. Thromb. Haemost. 23: 583 590.
76. Vasse, M.,, E. Guegan-Massardier,, J.-Y. Borg,, F. Woimant,, and C. Soria. 2001. Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet 357: 933 934.
77. Wakefield, T.W.,, R.M. Strieter,, R. Schaub,, D. D. Myers,, M. R. Prince,, S. K. Wrobleski,, F. J. Londy,, A. M. Kadell,, S. L. Brown,, P. K. Henke,, and L. J. Greenfield. 2000. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J.Vasc. Surg. 31: 309 324.
78. Walsh, P. N. 1987. Platelet-mediated trigger mechanisms in the contact phase of blood coagulation. Sem. Thromb. Hemost. 13: 86 94.
79. Waugh, J. M.,, E. Yuksel,, J. Li,, M. D. Kuo,, M. Kattash,, R. Saxena,, R. Geske,, S. N. Thung,, S. M. Shenaq,, and S. L. Woo. 1999. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ. Res. 84: 84 92.
80. Waugh, J. M.,, J. Li-Hawkins,, E. Yuksel,, M. D. Kuo,, P. N. Cifra,, P. R. Hilfiker,, R. Geske,, M. Chawla,, J. Thomas,, S. M. Shenaq,, M. D. Dake,, and S. L. Woo. 2000. Thrombomodulin overexpression to limit neointima formation. Circulation 102: 332 337.
81. Wen, D.,, W. A. Dittman,, R. D. Ye,, L. L. Deaven,, P. W. Majerus,, and J. E. Sadler. 1987. Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. Biochemistry 26: 4350 4357.
82. White, B.,, M. Schmidt,, C. Murphy,, W. Livingstone,, D. O'Toole,, M. Lawler,, L. O'Neill,, D. Kelleher,, H. P. Schwarz,, and O. P. Smith. 2000. Activated protein C inhibits lipopolysaccharideinduced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br. J. Haematol. 110: 130 134.
83. Wolbink, G.-J.,, A. W. J. Bossink,, A. B. J. Groeneveld,, M. C. M. DeGroot,, L. G. Thijs,, and C. E. Hack. 1998. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J. Infect. Dis. 177: 81 87.
84. Xu, J.,, D. Qu,, N. L. Esmon,, and C. T. Esmon. 1999. Metalloproteolytic release of endothelial cell protein C receptor. J. Biol. Chem. 275: 6038 6044.
85. Yamauchi, T.,, F. Umeda,, T. Inoguchi,, and H. Nawata. 1989. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem. Biophys. Res. Commun. 163: 1404 1411.
86. Yin, Z.-F.,, Z.-F. Huang,, J. Cui,, R. Fiehler,, N. Lasky,, and D. Ginsburg. 2000. Prothrombotic phenotype of protein Z deficiency. Proc. Natl. Acad. Sci. USA 97: 6734 6738.
87. Yuksel, M.,, K. Okajima,, M. Uchiba,, S. Horiuchi,, and H. Okabe. 2002. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytes. Thromb. Haemost. 88: 267 273.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error